(₹ crores) | Q1FY26 | Q4FY25 | Q1FY25 | QoQ (%) | YoY (%) |
---|---|---|---|---|---|
Total Income | 53.13 | 43.83 | 41.61 | 21.2% | 27.7% |
Total Expenses | 47.74 | 39.04 | 36.91 | 22.3% | 29.3% |
Profit Before Tax | 5.38 | 4.80 | 4.70 | 12.1% | 14.5% |
Tax | 0.71 | 1.67 | 2.29 | -57.5% | -69.0% |
Profit After Tax | 4.67 | 3.12 | 2.41 | 49.7% | 93.8% |
Earnings Per Share | 2.10 | 1.40 | 1.10 | 50.0% | 90.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Sakar Healthcare Ltd is a pharmaceutical company based in India. The company is primarily engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations. These formulations include tablets, capsules, dry powders, and liquid injectables, serving both the domestic and international markets. As a participant in the healthcare and pharmaceutical industry, Sakar Healthcare Ltd focuses on the development and production of generic drugs. The company has been involved in various expansions and developments to enhance its production capabilities and market reach. However, specific recent major developments are not available in the current dataset.
For the first quarter of the fiscal year 2026 (Q1FY26), Sakar Healthcare Ltd reported a total income of ₹53.13 crores. This marks a significant increase from both the previous quarter (Q4FY25), which recorded ₹43.83 crores, and the same quarter in the previous year (Q1FY25), which was ₹41.61 crores. The quarter-over-quarter (QoQ) growth of total income stands at 21.2%, while the year-over-year (YoY) growth is 27.7%. These figures reflect a consistent upward trajectory in revenue generation for the company over the provided periods.
Sakar Healthcare Ltd's profitability metrics for Q1FY26 show a profit before tax (PBT) of ₹5.38 crores. This is an improvement from ₹4.80 crores in Q4FY25 and ₹4.70 crores in Q1FY25. The PBT has increased by 12.1% QoQ and 14.5% YoY. The company's tax expenses for Q1FY26 were significantly lower at ₹0.71 crores compared to ₹1.67 crores in Q4FY25 and ₹2.29 crores in Q1FY25. Consequently, the profit after tax (PAT) for Q1FY26 rose to ₹4.67 crores, a 49.7% increase QoQ and a 93.8% increase YoY. The earnings per share (EPS) also reflect robust growth, rising to ₹2.10 in Q1FY26 from ₹1.40 in Q4FY25 and ₹1.10 in Q1FY25, indicating a 50.0% QoQ growth and a 90.9% YoY increase.
The total expenses for Sakar Healthcare Ltd in Q1FY26 were reported at ₹47.74 crores, up from ₹39.04 crores in Q4FY25 and ₹36.91 crores in Q1FY25. This represents a 22.3% QoQ increase and a 29.3% YoY increase in expenses. Despite the rise in expenses, the company managed to maintain a healthy profit margin due to the substantial increase in total income and reduced tax expenses. No detailed breakdown of operating metrics such as cost of goods sold, operating income, or specific operational efficiencies is provided in the data.
Sakar Healthcare Ltd announced its Q1 FY 2025-26 results on 14 August, 2025.
Sakar Healthcare Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Sakar Healthcare Ltd Q1 FY 2025-26 results include:
Sakar Healthcare Ltd reported a net profit of ₹4.67 crore in Q1 FY 2025-26, reflecting a 93.8% year-over-year growth.
Sakar Healthcare Ltd posted a revenue of ₹53.13 crore in Q1 FY 2025-26.